Covered recipient · General Payments record
JOHN P BERDAHL
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$141,870.19
58 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $83,560.00 | 27 |
| Royalty or License | $40,000.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,325.00 | 4 |
| Honoraria | $5,250.00 | 4 |
| Travel and Lodging | $1,034.46 | 8 |
| Food and Beverage | $700.73 | 14 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alcon Vision LLC | $82,727.50 | 25 |
| Alcon Research LLC | $34,151.14 | 7 |
| Glaukos Corporation | $14,019.94 | 9 |
| Ocular Therapeutix, Inc. | $5,538.51 | 5 |
| Allergan, Inc. | $2,360.00 | 3 |
| RxSight Inc | $1,250.00 | 1 |
| Sight Sciences, Inc. | $1,140.23 | 2 |
| Johnson & Johnson Surgical Vision, Inc. | $600.00 | 1 |
| NEW WORLD MEDICAL,INC. | $41.01 | 2 |
| Novartis Pharmaceuticals Corporation | $26.49 | 2 |
| Omeros Corporation | $15.37 | 1 |
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN P BERDAHL
NPI 1871761577 · CMS profile ID 130878
Allopathic & Osteopathic Physicians / Ophthalmology
SIOUX FALLS, SD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1871761577?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN P BERDAHL, NPI 1871761577, CMS profile ID 130878. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871761577?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JOHN P BERDAHL, NPI 1871761577, CMS profile ID 130878. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871761577?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JOHN P BERDAHL, NPI 1871761577, CMS profile ID 130878, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1871761577?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
58 matching records · $141,870.19 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–58 of 58.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alcon Vision LLC | $37.20 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 729623015 | CMS |
| Alcon Vision LLC | $53.21 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 729630967 | CMS |
| NEW WORLD MEDICAL,INC. | $27.01 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753244097 | CMS |
| Alcon Vision LLC | $32.23 | 01/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 729626651 | CMS |
| Alcon Vision LLC | $54.00 | 01/19/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721128675 | CMS |
| Alcon Vision LLC | $71.56 | 01/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 729619271 | CMS |
| Alcon Vision LLC | $54.00 | 01/19/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753938074 | CMS |
| NEW WORLD MEDICAL,INC. | $14.00 | 01/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753244095 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $526,683.74 | 94 |
| PY2024 | Principal investigator | $911,748.47 | 469 |
| PY2023 | Principal investigator | $736,016.38 | 172 |
| PY2022 | Recipient | $108.50 | 1 |
| PY2022 | Principal investigator | $337,192.11 | 53 |
| PY2021 | Principal investigator | $519,228.22 | 81 |
| PY2020 | Principal investigator | $575,164.46 | 72 |
| PY2019 | Recipient | $22,593.79 | 3 |
| PY2019 | Principal investigator | $558,559.20 | 98 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
94 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $11,024.53 | 12/31/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1202532887 |
| Principal investigator 1 | Glaukos Corporation | $2,270.00 | 12/10/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906189 |
| Principal investigator 1 | Glaukos Corporation | $90.00 | 11/26/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910551 |
| Principal investigator 1 | Glaukos Corporation | $3,880.00 | 11/19/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Follow-up of Eyes that Received Epithelium-on Corneal Collagen Cross-Linking Treatment in Study GLK-202-04 | No dispute reported | 06/30/2026 | 1250906016 |
| Principal investigator 1 | Glaukos Corporation | $8,295.00 | 11/19/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906181 |
| Principal investigator 1 | Glaukos Corporation | $360.00 | 10/22/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910543 |
| Principal investigator 1 | Glaukos Corporation | $731.89 | 10/15/2025 | Non-covered Recipient Entity Konan Medical, USA, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250907486 |
| Principal investigator 1 | Glaukos Corporation | $9,530.00 | 10/08/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906173 |
| Principal investigator 1 | Glaukos Corporation | $1,440.00 | 10/08/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906177 |
| Principal investigator 1 | Glaukos Corporation | $2,895.00 | 09/17/2025 | Non-covered Recipient Entity Konan Medical, USA, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250907482 |
| Principal investigator 1 | Glaukos Corporation | $2,190.00 | 09/10/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906157 |
| Principal investigator 1 | Alcon Research LLC | $1,000.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1220924320 |
| Principal investigator 1 | Alcon Research LLC | $500.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1220924322 |
| Principal investigator 1 | Alcon Research LLC | $2,000.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1220924324 |
| Principal investigator 1 | Alcon Research LLC | $1,000.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1220924340 |
| Principal investigator 1 | Alcon Research LLC | $750.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1220924342 |
| Principal investigator 1 | Alcon Research LLC | $1,500.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1220924344 |
| Principal investigator 1 | Alcon Research LLC | $706.44 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069398 |
| Principal investigator 1 | Alcon Research LLC | $106,074.38 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069400 |
| Principal investigator 1 | Alcon Research LLC | $2,218.18 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069402 |
| Principal investigator 1 | Alcon Research LLC | $10,911.22 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069404 |
| Principal investigator 1 | Alcon Research LLC | $40,383.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069406 |
| Principal investigator 1 | Alcon Research LLC | $6,027.36 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069408 |
| Principal investigator 1 | Alcon Research LLC | $11,213.68 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069410 |
| Principal investigator 1 | Alcon Research LLC | $2,657.50 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069412 |
| Principal investigator 1 | Alcon Research LLC | $3,807.76 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069414 |
| Principal investigator 1 | Alcon Research LLC | $2,825.76 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069416 |
| Principal investigator 1 | Alcon Research LLC | $437.08 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069418 |
| Principal investigator 1 | Alcon Research LLC | $1,412.88 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069420 |
| Principal investigator 1 | Alcon Research LLC | $62.70 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069422 |
| Principal investigator 1 | Alcon Research LLC | $6,945.88 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069424 |
| Principal investigator 1 | Alcon Research LLC | $395.57 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069426 |
| Principal investigator 1 | Alcon Research LLC | $593.35 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069428 |
| Principal investigator 1 | Alcon Research LLC | $11.80 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069430 |
| Principal investigator 1 | Alcon Research LLC | $12.60 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069432 |
| Principal investigator 1 | Alcon Research LLC | $44.05 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069434 |
| Principal investigator 1 | Alcon Research LLC | $11.66 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069436 |
| Principal investigator 1 | Alcon Research LLC | $706.44 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069438 |
| Principal investigator 1 | Alcon Research LLC | $706.44 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069440 |
| Principal investigator 1 | Alcon Research LLC | $45,743.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069442 |
| Principal investigator 1 | Alcon Research LLC | $1,109.09 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069444 |
| Principal investigator 1 | Alcon Research LLC | $10,911.22 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069446 |
| Principal investigator 1 | Alcon Research LLC | $3,013.68 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069448 |
| Principal investigator 1 | Alcon Research LLC | $3,807.76 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069450 |
| Principal investigator 1 | Alcon Research LLC | $706.44 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069452 |
| Principal investigator 1 | Alcon Research LLC | $706.44 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069454 |
| Principal investigator 1 | Alcon Research LLC | $45,743.00 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069456 |
| Principal investigator 1 | Alcon Research LLC | $1,109.09 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069458 |
| Principal investigator 1 | Alcon Research LLC | $5,455.61 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069460 |
| Principal investigator 1 | Alcon Research LLC | $3,013.68 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069462 |
| Principal investigator 1 | Alcon Research LLC | $3,807.76 | 08/28/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | User Product Evaluation Protocol | No dispute reported | 06/30/2026 | 1237069464 |
| Principal investigator 1 | Glaukos Corporation | $90.00 | 08/13/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910819 |
| Principal investigator 1 | Glaukos Corporation | $1,200.00 | 08/06/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906153 |
| Principal investigator 1 | ABBVIE INC. | $13,579.00 | 08/05/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION CLINIC | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1202501980 |
| Principal investigator 1 | Glaukos Corporation | $270.00 | 07/16/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910747 |
| Principal investigator 1 | Glaukos Corporation | $4.71 | 07/09/2025 | Non-covered Recipient Entity Amazon.com, Inc. | A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus | No dispute reported | 06/30/2026 | 1250908936 |
| Principal investigator 1 | Glaukos Corporation | $1,130.00 | 07/02/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906151 |
| Principal investigator 1 | Glaukos Corporation | $5,645.00 | 07/02/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906170 |
| Principal investigator 1 | Glaukos Corporation | $1,250.00 | 07/02/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906321 |
| Principal investigator 1 | Glaukos Corporation | $517.24 | 06/04/2025 | Non-covered Recipient Entity Greenphire, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250903988 |
| Principal investigator 1 | Glaukos Corporation | $1,200.00 | 06/04/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906146 |
| Principal investigator 1 | Glaukos Corporation | $1,286.62 | 06/04/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906306 |
| Principal investigator 1 | Glaukos Corporation | $270.00 | 06/04/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910737 |
| Principal investigator 1 | Glaukos Corporation | $805.00 | 05/07/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906143 |
| Principal investigator 1 | Glaukos Corporation | $40,775.00 | 05/07/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906161 |
| Principal investigator 1 | Glaukos Corporation | $375.00 | 05/07/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250906166 |
| Principal investigator 1 | Glaukos Corporation | $3,950.00 | 05/07/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906301 |
| Principal investigator 1 | Glaukos Corporation | $450.00 | 04/29/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910729 |
| Principal investigator 1 | Glaukos Corporation | $517.24 | 04/02/2025 | Non-covered Recipient Entity Greenphire, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250904539 |
| Principal investigator 1 | Glaukos Corporation | $980.00 | 04/02/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906617 |
| Principal investigator 1 | Glaukos Corporation | $2,500.00 | 04/02/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906724 |
| Principal investigator 1 | Glaukos Corporation | $5,000.00 | 04/02/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906788 |
| Principal investigator 1 | Glaukos Corporation | $231.00 | 03/25/2025 | Non-covered Recipient Entity InComm Digital Solutions, LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250907572 |
| Principal investigator 1 | Glaukos Corporation | $2.66 | 03/19/2025 | Non-covered Recipient Entity Amazon.com, Inc. | A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus | No dispute reported | 06/30/2026 | 1250909323 |
| Principal investigator 1 | ABBVIE INC. | $650.00 | 03/13/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION CLINIC | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1202463104 |
| Principal investigator 1 | Alcon Research LLC | $28,600.00 | 03/13/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | Clareon PanOptix Pro: Early bilateral Clinical Experience | No dispute reported | 06/30/2026 | 1220924168 |
| Principal investigator 1 | Glaukos Corporation | $258.62 | 03/12/2025 | Non-covered Recipient Entity Greenphire, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250905028 |
| Principal investigator 1 | ABBVIE INC. | $1,252.00 | 03/06/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION CLINIC | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1202456707 |
| Principal investigator 1 | Glaukos Corporation | $2,470.34 | 03/05/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus | No dispute reported | 06/30/2026 | 1250906430 |
| Principal investigator 1 | Glaukos Corporation | $580.00 | 03/05/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906613 |
| Principal investigator 1 | Glaukos Corporation | $258.62 | 02/19/2025 | Non-covered Recipient Entity Greenphire, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250904916 |
| Principal investigator 1 | Glaukos Corporation | $421.30 | 02/19/2025 | Non-covered Recipient Entity Commercial Print Management | Multicenter, Randomized, Double-masked, Parallel Group Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intracameral implant) in Conjunction with Cataract Surgery vs. Cataract Surgery Alone | No dispute reported | 06/30/2026 | 1250907816 |
| Principal investigator 1 | Glaukos Corporation | $1,330.00 | 02/12/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906609 |
| Principal investigator 1 | Glaukos Corporation | $8,950.00 | 02/12/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906721 |
| Principal investigator 1 | ABBVIE INC. | $12,660.00 | 02/05/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION CLINIC | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1202444671 |
| Principal investigator 1 | Glaukos Corporation | $258.62 | 01/29/2025 | Non-covered Recipient Entity Greenphire, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250904801 |
| Principal investigator 1 | Alcon Research LLC | $4,000.00 | 01/09/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | Unity VCS Cataract Claims Study | No dispute reported | 06/30/2026 | 1220924162 |
| Principal investigator 1 | Alcon Research LLC | $1,200.00 | 01/09/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | Unity VCS Cataract Claims Study | No dispute reported | 06/30/2026 | 1220924164 |
| Principal investigator 1 | Alcon Research LLC | $200.00 | 01/09/2025 | Non-covered Recipient Entity VANCE THOMPSON VISION | Unity VCS Cataract Claims Study | No dispute reported | 06/30/2026 | 1220924166 |
| Principal investigator 1 | Glaukos Corporation | $258.62 | 01/08/2025 | Non-covered Recipient Entity Greenphire, Inc. | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250905487 |
| Principal investigator 1 | Glaukos Corporation | $3,405.00 | 01/08/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | A Phase 3, Multi-center, Randomized, Double-masked, Placebo/Sham-controlled Study to Evaluate the Safety and Efficacy of Oxygen Enriched, Non-invasive Epithelium-on Corneal Collagen Cross-linking in Eyes with Keratoconus | No dispute reported | 06/30/2026 | 1250906411 |
| Principal investigator 1 | Glaukos Corporation | $3,320.00 | 01/08/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension | No dispute reported | 06/30/2026 | 1250906605 |
| Principal investigator 1 | Glaukos Corporation | $1,383.23 | 01/08/2025 | Non-covered Recipient Entity Vance Thompson Vision Clinic, Prof LLC | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250906717 |
| Principal investigator 1 | Glaukos Corporation | $450.00 | 01/08/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study | No dispute reported | 06/30/2026 | 1250910947 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $50,050.00 | 1 |
| PY2024 | Value of interest | $62,500.00 | 1 |
| PY2023 | Amount invested | $50,050.00 | 1 |
| PY2023 | Value of interest | $60,000.00 | 1 |
| PY2022 | Amount invested | $50,050.00 | 2 |
| PY2022 | Value of interest | $80,711.00 | 2 |
| PY2021 | Amount invested | $99,950.00 | 3 |
| PY2021 | Value of interest | $77,243.90 | 3 |
| PY2020 | Amount invested | $49,950.00 | 2 |
| PY2020 | Value of interest | $24,518.90 | 2 |
| PY2019 | Amount invested | $49,950.00 | 1 |
| PY2019 | Value of interest | $16.20 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
10 records · PY2019–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | TearOptix, Inc. | $50,050.00 | $62,500.00 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1145282167 |
| PY2023 | TearOptix, Inc. | $50,050.00 | $60,000.00 | Common Stock and Preferred Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1039880037 |
| PY2022 | RxSight Inc | $0.00 | $30,661.00 | Fully Vested Options | Physician Covered Recipient | No dispute reported | 06/30/2026 | 958919049 |
| PY2022 | TearOptix, Inc. | $50,050.00 | $50,050.00 | Common and Preferred Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 957785969 |
| PY2021 | Rapid Pathogen Screening, Inc. | $49,950.00 | $18.90 | common stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 760993610 |
| PY2021 | RxSight Inc | $0.00 | $27,225.00 | Fully Vested Options | Physician Covered Recipient | No dispute reported | 06/30/2026 | 849773681 |
| PY2021 | TearOptix, Inc. | $50,000.00 | $50,000.00 | Preferred Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 835516489 |
| PY2020 | Rapid Pathogen Screening, Inc. | $49,950.00 | $18.90 | common stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 737343809 |
| PY2020 | RxSight Inc | $0.00 | $24,500.00 | Fully Vested Options | Physician Covered Recipient | No dispute reported | 06/30/2026 | 752951863 |
| PY2019 | Rapid Pathogen Screening, Inc. | $49,950.00 | $16.20 | common stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 651528363 |